Alfred di Stefano, MD
Hematology & Oncology · Arlington, TXNPI 1104828664
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $478 and has fallen 83.6% since, to $79 in 2023. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 32 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$128
- Novartis$69
- Lilly USA, LLC$61
- Genentech USA, Inc.$60
- Abbott$49
- Pharmacyclics LLC, An Abbvie Company$41
- plus $240 from 13 others
Across 6 payments — averaging $1038.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$4K
- E.r. Squibb & Sons, L.L.C.$1K
- Astrazeneca UK Limited$1K
What the payments were for
- Food & beverage$59592%
- Education$528%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $128 |
| Novartis | 4 | $69 |
| Lilly USA, LLC | 4 | $61 |
| Genentech USA, Inc. | 2 | $60 |
| Abbott | 2 | $49 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $41 |
| Incyte Corporation | 2 | $34 |
| Gilead | 1 | $27 |
| Pfizer | 2 | $25 |
| Morphosys, US Inc. | 1 | $22 |
| Exelixis Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Merck | 1 | $16 |
| Blue Earth Diagnostics | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| EMD Serono, Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
How this compares
$647 in reported general payments places this provider in the 25th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 36 | $535 |
| Allopurinol | 11 | $228 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Arlington
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.